- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04175028
Neuromodulation of Executive Function in the ADHD Brain
March 20, 2024 updated by: Joan A Camprodon, MD MPH PhD, Massachusetts General Hospital
This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD compared to healthy controls.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This study aims to determine the transient, modulatory effects of transcranial direct current stimulation (tDCS) on executive function and inhibitory control in patients with ADHD.
Deficits in these cognitive functions are core to ADHD, and cause significant impairment and morbidity.
The study will also include a cohort of healthy controls for comparison.
Study Type
Interventional
Enrollment (Estimated)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Patricia Cirillo, MD, PhD
- Phone Number: 6177243217
Study Contact Backup
- Name: Joan Camprodon, MD, PhD, MPH
- Phone Number: 61772656348
- Email: jcamprodon@mgh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02129
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Blake Andreou, BS
- Phone Number: 617-724-8780
- Email: bandreou@mgh.harvard.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 66 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria
- Male and female subjects 18-66 years of age
- Healthy volunteers or volunteers with a diagnosis of ADHD in adulthood, meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) [American Psychiatric Association, 2013] criteria, including at least 5 moderate inattentive or impulsive-hyperactive symptoms, and onset of two symptoms of inattentive or of impulsive/hyperactive traits by the age of 12.
- Patient will be either off stimulant medications or, if undergoing treatment with stimulants, will be asked to discontinue two days prior to the experiment, under physician-guided protocol, and allowed to resume afterwards. Subjects may resume stimulant use between the two study visits so long as they discontinue use two days prior to the second study visit. If fatigue is problematic in subjects discontinuing medication, they will be allowed to continue with the study if they are able to follow the suggested taper plan (50% of the dose day one, 25% dose day 2, stop day of visit (day 3)).
- English-speaking
Exclusion Criteria
- Current or past history of clinically unstable psychiatric conditions such as suicidal or homicidal behavior or psychotic disorders.
- Pregnant or nursing females.
- Inability to participate in testing procedures
- Contraindication to tDCS: history or epilepsy, metallic implants in the head and neck, brain stimulators, vagus nerve stimulators, VP shunt, pacemakers, pregnancy.
Additional exclusion criteria for healthy controls:
- Diagnosis of psychiatric of neurological disorder
- Ongoing treatment with any psychotropic medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: ADHD
Patients with ADHD.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
|
Other: Healthy Control
Volunteers without Neuropsychiatric Disorders.
|
In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Accuracy and Reaction Time in Attention and Working Memory
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
N-Back Task
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Change in Accuracy and Reaction Time in Attention and Working Memory
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Flanker Task
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Change in Accuracy and Reaction Time in Attention and Working Memory
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Multi-Source Interference with International Affective Picture System Task
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Change in Accuracy and Reaction Time in Inhibition/Decision Making
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Delayed Discounting
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Change in Accuracy and Reaction Time in Inhibition/Decision Making
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Stop Signal Task
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Change in Accuracy and Reaction Time in Inhibition/Decision Making
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Cambridge Gambling Task
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Amplitude of Encephalogram (EEG) Event Related Potentials
Time Frame: Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Measure of amplitude related to stimulus
|
Change Before and After Stimulation on Each of the Three Visits, Average 2-6 Weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Joan Camprodon, MD, PhD, MPH, Massachusetts General Hospital
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2014
Primary Completion (Estimated)
September 1, 2024
Study Completion (Estimated)
September 1, 2024
Study Registration Dates
First Submitted
November 18, 2019
First Submitted That Met QC Criteria
November 20, 2019
First Posted (Actual)
November 22, 2019
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014P001401
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Attention Deficit Hyperactivity Disorder
-
Cingulate TherapeuticsRecruitingPhase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301ADHD | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Ornit CohenUnknownAttention Deficit Hyperactivity Disorder | Attention Deficit Disorder With Hyperactivity | Attention Deficit Disorder | Attention Deficit Disorders With Hyperactivity | Attention Deficit Hyperactivity DisordersIsrael
-
Cingulate TherapeuticsPremier Research Group plcActive, not recruitingADHD | Attention Deficit Hyperactivity Disorder | ADHD - Combined Type | Attention Deficit Hyperactivity Disorder Combined | Attention Deficit Hyper Activity | Attention-deficit HyperactivityUnited States
-
Children's National Research InstituteRecruitingADHD | Attention Deficit Hyperactivity Disorder | Attention-Deficit Hyperactivity Disorder | Attention Deficit Disorder | ADD | ADHD Predominantly Inattentive Type | ADHD - Combined Type | ADHD, Predominantly Hyperactive - Impulsive | Attention-Deficit Disorder in Adolescence | Attention-Deficit Hyperactivity...United States
-
Fondation LenvalCompletedAttention Deficit Disorder With Hyperactivity | Attention Deficit Disorder Without HyperactivityFrance
-
University Hospital Bispebjerg and FrederiksbergMental Health Services in the Capital Region, DenmarkRecruitingSleep Disturbance | Neurodevelopmental Disorders | Attention Deficit Hyperactivity Disorder | Attention Deficit Disorder | Attention-Deficit Hyperactivity Disorder, Unspecified Type | Attention-deficit Hyperactivity | Hyperkinetic Conduct DisorderDenmark
-
Corium, Inc.Worldwide Clinical Trials; Premier Research Group plc; Almac; Prometrika, LLCRecruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Corium, Inc.Premier Research Group plc; Almac; Prometrika, LLCActive, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Massachusetts General HospitalShire Human Genetic Therapies, Inc.Active, not recruitingAttention Deficit/Hyperactivity DisorderUnited States
-
Ataturk UniversityCompletedAttention-deficit/Hyperactivity DisorderTurkey
Clinical Trials on Transcranial Direct Current Stimulation
-
Federal University of ParaíbaCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development...Recruiting
-
University of Campinas, BrazilUnknownEpilepsy IntractableBrazil
-
Dina Hatem ElhammadyUnknown
-
Shirley Ryan AbilityLabNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedStroke | Nonfluent AphasiaUnited States
-
University of Texas Rio Grande ValleyRecruitingSpinal Cord Diseases | Spinal Cord InjuriesUnited States
-
Federal University of ParaíbaUnknown
-
University of CalgaryAlberta Health servicesRecruitingCervicogenic HeadacheCanada
-
Universidade Federal do Rio Grande do NorteNot yet recruitingLow Back Pain | Transcranial Direct Current Stimulation
-
Nanyang Technological UniversityActive, not recruiting